Industry News

The US Food and Drug Administration (USFDA) has approved Aurobindo Pharma to market generic version of Prilosec delayed-release capsules used to treat ulcer.

Trivitron Healthcare, India’s largest medical technology company was honoured with 'Make In India Awards for Excellence' in the medical device manufacturing category.

[adsense:336x280:8701650588]

Eli Lilly and Company, a global healthcare leader, has launched
Humalog 200 units/ml KwikPen (insulin lispro 200 units/m; U-200), the first and only concentrated mealtime insulin analog in the US.

The US Food and Drug Administration (FDA) has accepted leading global pharmaceutical company, Teva Pharmaceutical Industries Ltd's New Drug Application (NDA) for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD). It is  a rare and fatal neurodegenerative disorder caused by the progressive breakdown of nerve cells in the brain that affects about five to seven people per 100,000 in western countries, according to the World Health Organisation.

focus in the areas of pain management and addiction medicine, announced the approval by the US Food and Drug Administration (FDA) of a Supplemental New Drug Application (sNDA) for a new formulation of Onsolis (fentanyl buccal soluble film) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant. Onsolis is separately licensed by BDSI in Taiwan and South Korea.

Dabur India Ltd, in an effort to ensure maximum use of its leading mosquito repellant Odomos, has unveiled the Dengue-Fighters initiative aimed at preventing school-going children across the country. The company along with Apollo Hospitals Group began its campaign in Bengaluru, which will then cover schools across Delhi, Uttar Pradesh, Maharashtra and Tamil Nadu.

A new medication to be launched by the end of this year by US Pharma major Eli Lilly, for diabetic patients in India. A regulatory approval for the upcoming product has already been received by the company. It is also gearing up to introduce another medication in oncology that could be launched by the end of 2016 or early 2017 which has been filed for approvals.

Generic Pramipexole dihydrochloride extended-release tablets for treatment of Parkinson's disease has been launched by Dr Reddy's Laboratories in the US market.